2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchMeSH KeywordsFemaleGender IdentityHumansMaleNicotineReceptors, AndrogenSmoking CessationSmoking PreventionSubstance Withdrawal SyndromeConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomenMood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states
Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS. Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacology 2015, 96: 235-243. PMID: 25582289, PMCID: PMC4486625, DOI: 10.1016/j.neuropharm.2014.12.028.Peer-Reviewed Original ResearchMeSH KeywordsAffectAggressionAnimalsAnxietyClinical Trials as TopicHumansNicotineNicotinic AgonistsReceptors, NicotinicSubstance Withdrawal SyndromeTobacco Use DisorderConceptsNicotinic acetylcholine receptorsNicotinic medicationsAcetylcholine receptorsNicotinic agentsRole of nAChRsEffects of nicotineBehavioral statesSelf-medicate symptomsNicotinic effectsClinical trialsClinical studiesMood disordersPsychiatric disordersAnimal modelsAffective disordersMedicationsTobacco productsAnxiety regulationRelated constructsMental statesReceptorsDisordersNAChRsNicotineMood
2013
Morphine dependence and withdrawal induced changes in cholinergic signaling
Neugebauer NM, Einstein EB, Lopez MB, McClure-Begley TD, Mineur YS, Picciotto MR. Morphine dependence and withdrawal induced changes in cholinergic signaling. Pharmacology Biochemistry And Behavior 2013, 109: 77-83. PMID: 23651795, PMCID: PMC3690589, DOI: 10.1016/j.pbb.2013.04.015.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcholineAnimalsBehavior, AnimalMaleMiceMice, Inbred C57BLMorphineMorphine DependenceNaloxoneNarcotic AntagonistsReceptors, NicotinicSignal TransductionSubstance Withdrawal SyndromeConceptsMedial habenulaMorphine dependenceCholinergic signalingInterpeduncular nucleusHigh-affinity nicotinic acetylcholine receptorsNicotinic acetylcholine receptor levelsEffects of cholinergicMorphine-dependent miceChronic morphine administrationAcetylcholine receptor levelsC-fos expressionC-Fos activationNicotinic acetylcholine receptorsDependent miceMorphine administrationMorphine withdrawalCholinergic drugsOpiate withdrawalCholinergic systemEpibatidine bindingReceptor levelsSomatic signsNeuronal activityAcetylcholine receptorsNAChR receptor
2012
Sex Differences in Availability of β2*-Nicotinic Acetylcholine Receptors in Recently Abstinent Tobacco Smokers
Cosgrove KP, Esterlis I, McKee SA, Bois F, Seibyl JP, Mazure CM, Krishnan-Sarin S, Staley JK, Picciotto MR, O’Malley S. Sex Differences in Availability of β2*-Nicotinic Acetylcholine Receptors in Recently Abstinent Tobacco Smokers. JAMA Psychiatry 2012, 69: 418-427. PMID: 22474108, PMCID: PMC3508698, DOI: 10.1001/archgenpsychiatry.2011.1465.Peer-Reviewed Original ResearchMeSH KeywordsAdultAzetidinesBehavior, AddictiveBrainDepressionEstradiolFemaleFunctional NeuroimagingHumansIodine RadioisotopesMaleNicotinic AntagonistsProgesteronePyridinesRadioligand AssayReceptors, NicotinicSex CharacteristicsSmokingSubstance Withdrawal SyndromeTomography, Emission-Computed, Single-PhotonConceptsNAChR availabilityFemale smokersTobacco smokersNicotinic acetylcholine receptorsFemale nonsmokersProgesterone levelsAcetylcholine receptorsFemale sex steroid hormonesSex differencesSex steroid hormone levelsAbstinent tobacco smokersSex-matched nonsmokersTobacco smoking effectsMagnetic resonance imaging studyAge-matched malesEquilibrium distribution volumeEffects of nicotineSex steroid hormonesSteroid hormone levelsUnderlying neurochemical mechanismsResonance imaging studySingle photon emissionDays of abstinenceIA SPECTNicotine therapy
2011
Galanin negatively modulates opiate withdrawal via galanin receptor 1
Holmes FE, Armenaki A, Iismaa TP, Einstein EB, Shine J, Picciotto MR, Wynick D, Zachariou V. Galanin negatively modulates opiate withdrawal via galanin receptor 1. Psychopharmacology 2011, 220: 619-625. PMID: 21969124, PMCID: PMC3324978, DOI: 10.1007/s00213-011-2515-x.Peer-Reviewed Original ResearchConceptsGalanin receptor 1Chronic morphine administrationMorphine administrationLocus coeruleusGalanin expressionOpiate withdrawalReceptor 1Distinct G protein-coupled receptorsPrecipitation of withdrawalAction of morphineDoses of morphineWild-type miceTransgenic mouse lineG protein-coupled receptorsExpress galaninGalanin levelsWild-type controlsProtein-coupled receptorsNeuropeptide galaninMorphine dependenceWithdrawal signsOpiate dependenceGalaninTransgenic miceGalR2 gene
2010
Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler
Esterlis I, Mitsis EM, Batis JC, Bois F, Picciotto MR, Stiklus SM, Kloczynski T, Perry E, Seibyl JP, McKee S, Staley JK, Cosgrove KP. Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. The International Journal Of Neuropsychopharmacology 2010, 14: 389-398. PMID: 21029513, PMCID: PMC3510008, DOI: 10.1017/s1461145710001227.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdultBehavior, AddictiveFemaleHumansMaleMiddle AgedNicotineNicotinic AgonistsReceptors, NicotinicSmokingSmoking CessationSubstance Withdrawal SyndromeYoung AdultConceptsNicotine inhalerWithdrawal symptomsReceptor occupancyTobacco smokingLow nicotine cigarettesAdministration of nicotineHigh receptor occupancyDoses of nicotineNicotinic acetylcholine receptorsInhaler useTobacco smokersBaseline scanRegular cigarettesInhalerConstant infusionAcetylcholine receptorsSPECT studiesCigarettesSymptomsBeta 2Significant decreaseNicotineSignificant differencesSmokingNAChRs
2009
Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors
Picciotto MR, Brabant C, Einstein EB, Kamens HM, Neugebauer NM. Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors. Brain Research 2009, 1314: 206-218. PMID: 19699187, PMCID: PMC2819596, DOI: 10.1016/j.brainres.2009.08.033.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiogenic MonoaminesBrainGalaninHumansHypothalamo-Hypophyseal SystemLimbic SystemReceptors, GalaninStress, PsychologicalSubstance Withdrawal SyndromeSubstance-Related DisordersConceptsEffects of galaninStress-related behaviorsDrugs of abuseGalanin receptorsAbility of galaninPotential mechanismsAddiction-related disordersDrug-related behaviorsNumber of neuropeptidesGalanin effectsHPA axisMonoaminergic systemsDrug exposureTreatment of stressNeuronal activityGalaninBrain areasNeuronal functionBrain regionsAddictive drugsBrain circuitsNovel therapeuticsDrugsNeural activityReceptors
2008
Galanin – 25 years with a multitalented neuropeptide
Picciotto MR. Galanin – 25 years with a multitalented neuropeptide. Cellular And Molecular Life Sciences 2008, 65: 1872-1879. PMID: 18500649, PMCID: PMC11131873, DOI: 10.1007/s00018-008-8151-x.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcholineAlcohol DrinkingAnimalsDopamineGalaninHumansLocomotionMiceMorphineRewardSignal TransductionSubstance Withdrawal SyndromeSubstance-Related DisordersConceptsGalanin receptorsFood intakeOpiate rewardDrug rewardGalanin – 25 yearsAbility of neuropeptidesMesolimbic dopamine systemDrugs of abuseGalanin agonistsNoradrenergic neuronsDrug withdrawalStriatal slicesWithdrawal signsAnalgesic propertiesLocus coeruleusHypothalamic functionDopamine releaseDopamine systemGalaninNovel treatmentsPlace preferenceStress-related pathwaysFiring ratePotential targetWithdrawal
2006
Effect of cocaine self-administration on striatal PKA-regulated signaling in male and female rats
Lynch WJ, Kiraly DD, Caldarone BJ, Picciotto MR, Taylor JR. Effect of cocaine self-administration on striatal PKA-regulated signaling in male and female rats. Psychopharmacology 2006, 191: 263-271. PMID: 17180335, DOI: 10.1007/s00213-006-0656-0.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBehavior, AnimalBlotting, WesternCocaineCyclic AMP-Dependent Protein KinasesDopamine and cAMP-Regulated Phosphoprotein 32Dopamine Uptake InhibitorsFemaleMaleNucleus AccumbensPhosphorylationRatsRats, Sprague-DawleyReceptors, AMPASelf AdministrationSex FactorsSignal TransductionSubstance Withdrawal SyndromeNicotine withdrawal increases body weight, neuropeptide Y and Agouti-related protein expression in the hypothalamus and decreases uncoupling protein-3 expression in the brown adipose tissue in high-fat fed mice
Fornari A, Pedrazzi P, Lippi G, Picciotto MR, Zoli M, Zini I. Nicotine withdrawal increases body weight, neuropeptide Y and Agouti-related protein expression in the hypothalamus and decreases uncoupling protein-3 expression in the brown adipose tissue in high-fat fed mice. Neuroscience Letters 2006, 411: 72-76. PMID: 17052838, DOI: 10.1016/j.neulet.2006.10.014.Peer-Reviewed Original ResearchMeSH KeywordsAdipose Tissue, BrownAgouti Signaling ProteinAgouti-Related ProteinAnalysis of VarianceAnimalsBody WeightDietary FatsHypothalamusIntercellular Signaling Peptides and ProteinsIon ChannelsMaleMiceMice, Inbred C57BLMitochondrial ProteinsNeuropeptide YNicotineNicotinic AgonistsReceptors, Adrenergic, betaSubstance Withdrawal SyndromeUncoupling Protein 3ConceptsNicotine withdrawalBrown adipose tissueBody weightNeuropeptide YAdipose tissueOrexigenic peptides neuropeptide YHigh-fat fed miceChronic nicotine treatmentPeptides neuropeptide YHigh-fat dietAbility of nicotineBody weight regulationProtein 3 expressionAnorectic effectNicotine treatmentSmoking cessationFat dietFed miceHuman smokersNormal rodentsWeight regulationIncreased expressionProtein 3Protein expressionExposure resultsGalanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?
Holmes A, Picciotto MR. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? CNS & Neurological Disorders - Drug Targets 2006, 5: 225-32. PMID: 16611095, DOI: 10.2174/187152706776359600.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxiety DisordersBiogenic AminesBrainDepressive DisorderGalaninHumansStress, PsychologicalSubstance Withdrawal SyndromeSubstance-Related DisordersConceptsStress-related neural pathwaysBrain stress pathwaysSerotonin-producing neuronsDistribution of galaninDepression-related behaviorsDorsal raphe nucleusExpression of galaninAdministration of galaninNovel therapeutic targetDrug addictionPotential roleAnxiety-like responsesGalanin agonistsGalanin systemRaphe nucleusDopamine neuronsOpiate withdrawalLocus coeruleusNeuronal typesRodent modelsCurrent evidenceGalaninPsychiatric disordersTherapeutic targetOpiate reinforcement
2005
Galanin can attenuate opiate reinforcement and withdrawal
Picciotto MR, Hawes JJ, Brunzell DH, Zachariou V. Galanin can attenuate opiate reinforcement and withdrawal. Neuropeptides 2005, 39: 313-315. PMID: 15944028, DOI: 10.1016/j.npep.2004.12.001.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGalaninHumansMiceMice, KnockoutMice, TransgenicOpioid-Related DisordersSubstance Withdrawal SyndromeConceptsOpiate reinforcementGalanin receptor agonistAction of opiatesUseful therapeutic agentEndogenous galaninReceptor agonistGalaninKnockout miceBrain areasTransgenic miceBrain regionsBehavioral signsOpiate addictionTherapeutic agentsBody of dataAltered susceptibilityWithdrawalMiceReceptorsAgonistsOpiates
2003
The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal
Zachariou V, Brunzell DH, Hawes J, Stedman DR, Bartfai T, Steiner RA, Wynick D, Langel Ü, Picciotto MR. The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proceedings Of The National Academy Of Sciences Of The United States Of America 2003, 100: 9028-9033. PMID: 12853567, PMCID: PMC166432, DOI: 10.1073/pnas.1533224100.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBehavior, AnimalCoumarinsDopamine beta-HydroxylaseFemaleGalaninMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMorphineSubstance Withdrawal SyndromeConceptsMorphine withdrawal signsWithdrawal signsOpiate withdrawalGalanin agonistsEffects of galaninLocus coeruleus neuronsC-Fos immunoreactivityBlood-brain barrierEndogenous galaninMorphine withdrawalNoradrenergic neuronsCoeruleus neuronsC57BL/6 miceNeurochemical signsNeuropeptide galaninLocus coeruleusPossible molecular mechanismsTyrosine hydroxylaseGalaninNeuronal activityGalanin peptidePhysical signsTransgenic miceDrug dependenceBehavioral effects
2000
Upregulation of Galanin Binding Sites and GalR1 mRNA Levels in the Mouse Locus Coeruleus Following Chronic Morphine Treatments and Precipitated Morphine Withdrawal
Zachariou V, Thome J, Parikh K, Picciotto M. Upregulation of Galanin Binding Sites and GalR1 mRNA Levels in the Mouse Locus Coeruleus Following Chronic Morphine Treatments and Precipitated Morphine Withdrawal. Neuropsychopharmacology 2000, 23: 127-137. PMID: 10882839, DOI: 10.1016/s0893-133x(00)00094-4.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoradiographyBehavior, AnimalDrug Administration ScheduleFemaleGalaninIn Situ HybridizationIodine RadioisotopesLocus CoeruleusMiceMice, Inbred C57BLMorphineNaltrexoneNucleus AccumbensReceptors, GalaninReceptors, NeuropeptideRNA, MessengerSubstance Withdrawal SyndromeUp-RegulationVentral Tegmental AreaConceptsGalanin binding sitesLocus coeruleusMorphine treatmentMRNA levelsAcute morphine treatmentChronic morphine treatmentMouse locus coeruleusReceptor 1 geneLC neuronsMorphine administrationMorphine withdrawalNeuropeptide galaninOpiate withdrawalReceptor levelsBrain areasDrug dependenceGalaninCAMP levelsWithdrawalBinding sitesCoeruleusTreatmentLevelsGalR1Neurons
1998
Common aspects of the action of nicotine and other drugs of abuse
Picciotto M. Common aspects of the action of nicotine and other drugs of abuse. Drug And Alcohol Dependence 1998, 51: 165-172. PMID: 9716938, DOI: 10.1016/s0376-8716(98)00074-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnimalsAnti-Anxiety AgentsBehavior, AddictiveCentral Nervous System StimulantsCognitionHumansIllicit DrugsMotor ActivityNicotineNicotinic AgonistsNucleus AccumbensReceptors, NicotinicRewardSelf MedicationSubstance Withdrawal SyndromeSubstance-Related DisordersTobacco Use DisorderVentral Tegmental Area